Low-dose IL-34 has no effect on osteoclastogenesis but promotes osteogenesis of hBMSCs partly via activation of the PI3K/AKT and ERK signaling pathways

Jianxiang Xu

Zhejiang University School of Medicine Second Affiliated Hospital

Lifeng Fu

Zhejiang University School of Medicine Second Affiliated Hospital

Jinwu Bai

Zhejiang University School of Medicine Second Affiliated Hospital

Huiming Zhong

Zhejiang University School of Medicine Second Affiliated Hospital

Zhihui Kuang

Zhejiang University School of Medicine Second Affiliated Hospital

Chengwei Zhou

Zhejiang University School of Medicine Second Affiliated Hospital

Bin Hu

Zhejiang University School of Medicine Second Affiliated Hospital

Licheng Ni

Zhejiang University School of Medicine Second Affiliated Hospital

Li Ying

Zhejiang University School of Medicine Second Affiliated Hospital

Erman Chen

Zhejiang University School of Medicine Second Affiliated Hospital

Wei Zhang

Zhejiang University School of Medicine Second Affiliated Hospital

Jiaqi Wu

Zhejiang University School of Medicine Second Affiliated Hospital

Deting Xue

Zhejiang University School of Medicine Second Affiliated Hospital

Weixu Li

Zhejiang University School of Medicine Second Affiliated Hospital

zhijun pan (✉ zrpzj@zju.edu.cn)

Research

Keywords: Low-dose IL-34, hBMSCs, mBMMs, Osteoblastogenesis, Osteoclastogenesis

Posted Date: February 4th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-86672/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Abstract

Background: Inflammatory microenvironment is significant to the differentiation and function of mesenchymal stem cells (MSCs). It evidentially influences the osteoblastogenesis of MSCs. IL-34, a newly discovered cytokine, playing a key role in metabolism. However, the research on its functional role in the osteogenesis of MSCs was rarely reported. Here, we described the regulatory effects of low-dose IL-34 on both osteoblastogenesis and osteoclastogenesis.

Methods: We performed the osteogenic effects of hBMSCs by exogenous and overexpressed IL-34 *in vitro*, so was the osteoclastogenesis effects of mBMMs by extracellular IL-34. CCK-8 was used to assess the effect of IL-34 on the viability of hBMSCs and mBMMs. ALP staining, ARS and TRAP staining were used to evaluate ALP activity, mineral deposition and osteoclastogenesis, respectively. qRT-PCR and Western blotting analysis were performed to detect the expression of target genes and proteins. ELISA was used to evaluate the concentrations of IL-34. *In vivo*, a rat tibial osteotomy model and an OVX model were established. Radiographic analysis and histological evaluation were performed to confirm the therapeutic effects of IL-34 in fracture healing and osteoporosis. Statistical differences were evaluated by two-tailed Student's t-test, one-way ANOVA with Bonferroni's post hoc test and two-way ANOVA with Bonferroni multiple comparisons post hoc test in the comparison of 2 groups, more than 2 groups and different time points of treated groups, respectively.

Results: Promoted osteoblastogenesis of hBMSCs was observed after treated by exogenous or overexpressed IL-34 *in vitro*, confirmed by increased mineral deposits and ALP activity. Furthermore, exogenous or overexpressed IL-34 enhanced the expression of p-AKT and p-ERK. The specific AKT and ERK signaling pathway inhibitors suppressed the enhancement of osteoblastogenesis induced by IL-34. In a rat tibial osteotomy model, imaging and histological analyses testified the local injection of exogenous IL-34 improved bone healing. However, the additional IL-34 has no influence on both osteoclastogenesis of mBMMs *in vitro* and osteoporosis of OVX model of rat *in vivo*.

Conclusions: Collectively, our study demonstrate that low-dose IL-34 regulates osteogenesis of hBMSCs partly via the PIK/AKT and ERK signaling pathway and enhances fracture healing, with neither promoting nor preventing osteoclastogenesis *in vitro* and osteoporosis *in vivo*.

Introduction

Bone defects or fracture nonunion, which is still no efficacious way for the treatment, being one of the most intractable clinical diseases for orthopedic surgeons [1, 2]. Severe fracture, bone tumor ablation, debridement of a wide range of bone infections and congenital defects can lead to the failure of fracture healing [3]. Fracture healing is known as an intricate physiologic process that the vascularity at fracture site, mechanical environment, growth factors, scaffolds and mesenchymal stem cells (MSCs) coordinate spatially and temporally to work towards restoring bone structural integrity without scar formation [4, 5].

During fracture healing, the local fracture hematoma at a fracture site is rich in multiple cytokines, inflammatory factors, and many kinds of cells, which are helpful for bone and soft tissue repair [6]. Horst et al. [7] pointed out that there was evidential up-regulation of the concentrations of interleukin-6 (IL-6) and interleukin-8 (IL-8) in fracture hematomas when compared with the serum values in a combined trauma pig model. According to previous studies, IL-6 and IL-8 obviously affect the osteoblastogenesis and osteoclastogenesis [7-10]. Interleukin-34 (IL-34), a newly discovered cytokine, showing capable of inducing pro-inflammatory cytokines and chemokines such as IL-6 and IL-8 [11]. Thus, its osteogenic capacity should be explored further. Through comprehensive proteomic analyses, it was found to be the second ligand for colony-stimulating factor-1 receptor (CSF-1R). It binds to CSF-1R and possesses similar characteristics to CSF-1 in promoting monocyte viability and osteoclast generation [12, 13]. In the last few years, IL-34 has been gaining interest as a possible mediator for inflammatory arthritis (IA) [14-21]. It was reported that recombinant mouse IL-34 could induce the formation of osteoclasts *in vitro* and reduce trabecular bone mass *in vivo* [16]. In CSF-1^{op/op} mice, the presence of osteoclast precursors in the spleen seems to be supported by IL-34 expressed in vascular endothelial cells [22]. In addition, a study conducted by Cheng et al. [23] pointed out that IL-34 contributes to the survival of osteoclast progenitors, and *in vitro* it further promoted receptor activator of NF-κB ligand (RANKL)-induced osteoclasts via the JAK2/STAT3 pathway. Therefore, IL-34 may play a key role on osteoclastogenesis. In accordance with previous studies, the dynamic balance of bone metabolism continuously depends on the regulation between osteoclastic bone resorption and osteoblastic bone formation [24-26]. Nevertheless, the effects and molecular mechanisms of IL-34 on osteoblastogenesis remain unknown. Here, we present a study to describe the mechanisms underlying the role of IL-34 in osteogenesis in human bone marrow-derived mesenchymal stem cells (hBMSCs).

Bone marrow-derived mesenchymal stem cells (BMSCs), with self-renewal capabilities, are progenitors of osteoblasts, chondrocytes, and adipocytes, playing a key role in bone formation and remodeling for the healing of bone defects [27]. BMSCs not only differentiate into bone but also exert modulatory effects via a variety of mechanisms to promote bone healing [28]. As such, they represent an important source for potential therapeutic use [29]. Meanwhile, many cytokines and growth factors can affect the differentiation of BMSCs and improve the migration and homing of BMSCs for bone regeneration [30-32]. Recently, several studies noted that an inflammatory microenvironment can potentially increase the immunogenicity of BMSCs and decrease BMSCs viability and differentiation capacity [3, 8, 31].

The main goal of this research was to reveal a possible role of low-dose IL-34 in the molecular mechanisms on osteoblastogenesis and osteoclastogenesis. Our results founded that low-dose IL-34 regulates osteogenesis of hBMSCs partly via the PIK/AKT and ERK signaling pathway and enhances fracture healing, with neither promoting nor preventing osteoclastogenesis *in vitro* and osteoporosis *in vivo*.

Materials And Methods

Cell isolation, culture conditions, reagents, and antibodies

hBMSCs was provided by Cyagen Biosciences (Guangzhou, China), and it was confirmed as having the potential to induce the differentiation of osteoblasts, chondrocytes, and adipocytes. The cells were incubated in hBMSCs growth medium (Cyagen Biosciences, Guangzhou, China) at 37°C in a cell incubator containing 5% CO₂ with the medium being replaced every three days. Cells were trypsinized and passaged at nearly 80–90% confluence, and only passages three to seven were cultured in the follow-up experiments.

Six to eight-week-old male C57BL/6 mice were used for the isolation of primary murine bone monocyte/macrophage precursors as described [33]. Cells were differentiated into bone marrow-derived macrophages (BMMs) in complete Minimum essential medium Eagle Alpha modification (α-MEM, Gibco) containing 30 ng/ml of macrophage colony-stimulating factor (M-CSF) for 3–4 days at 37°C in a cell incubator with 5% CO₂, and the medium was replaced every two days.

Recombinant human IL-34 (rhIL-34) was purchased from Novus Biologicals(CO, USA). Recombinant murine M-CSF and recombinant murine RANKL were purchased from Novoprotein Biotechnology (Shanghai,China). A phospho-p44/42 MAPK (ERK1/2) inhibitor (U0126; Selleck Chemicals) and a phospho-Akt inhibitor (MK-2206 2HCL; Selleck Chemicals) were used in this study. Specific antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH), runt-related transcription factor 2 (RUNX2), collagen type I a 1 chain (COL1A1), extracellular signal-regulated kinase 1/2 (ERK1/2), phospho-ERK1/2, Phospho-P38 MAPK, P38 MAPK, Phospho–NF-κB P65, NF-κB P65, Non-phospho (active) β-catenin, β-catenin, protein kinase B (AKT), Phospho-AKT, Phospho-IκBα, IκBα, Phospho-SAPK/JNK, SAPK/JNK, Nuclear factor of activated T-cells cytoplasmic 1 (NFATc1/NFAT2), C-Src were purchased from Cell Signaling Technology (Danvers, MA, USA). Specific antibodies against C-Fos and Cathepsin K were obtained from Abcam(Cambridge, United Kingdom). Specific antibodies against PGC1β and IL-34 were obtained from Santa Cruz Biotechnology (Dallas, TX, USA).

Cytotoxicity assay

To evaluate the effects of IL-34 on the proliferation of hBMSCs and mice bone marrow-derived macrophages (mBMMs), a 96-well plate was applied to culture the cells with a density of 5×10^3 cells/well and 8×10^3 cells/well in triplicate, individually. After a 24-h period for adhesion, different concentrations of IL-34 (0, 0.0001, 0.001, 0.01 ng/ml) were performed for 1, 3, 5, or 7 days. Afterward, the medium was changed, and 10 μl Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) buffer was

added to each well, which was cultured for another four hours at 37°C. The optical density was measured on an ELX800 absorbance microplate reader (ELX808; BioTek, Winooski, VT, USA) at the wavelength of 450 nm (650 nm as reference).

Osteoblastogenesis assay

For the determination of osteoblast differentiation *in vitro*, 12-well cell culture plates were applied to culture hBMSCs with a density of $3 \times 10^4/\text{cm}^2$ at 37°C with 5% CO₂. After three days, the cells were incubated in osteogenic differentiation medium (ODM; Dulbecco's modified eagle medium; 10% fetal bovine serum, 100 nM dexamethasone, 10 mM β -glycerophosphate, 1% penicillin-streptomycin and 0.05 mM L-ascorbic acid-2-phosphate) with different concentrations of IL-34 (0, 0.0001, 0.001, 0.01 ng/ml). Cells with ODM only were regarded as controls, and the medium of the treated cells was changed every three days.

Three days later, Alkaline Phosphatase (ALP) staining was performed. The cells were first fixed with 4% paraformaldehyde for 15 min, washed twice by phosphate buffer saline (PBS), and washed again but with double distilled water (ddH₂O) every three minutes for three times. Then, the cells were stained with the BCIP/NBT ALP color development kit (Beyotime, Shanghai, China). In accordance with the manufacturer's instructions, ALP activity was calculated by the ALP Assay Kit (Beyotime, Shanghai, China) after the cells were lysed by lysis buffer including with 1% Triton X-100, 20 mM Tris-HCl (pH 7.5), and 150 mM NaCl. Finally, the ALP activity was calculated at 405 nm by a microplate reader (ELX808; BioTek).

After inducing osteogenic differentiation for 12 days, Alizarin Red Staining (ARS) Kit (Cyagen, Guangzhou, China) was performed. The cells were fixed with 4% paraformaldehyde for 15 min after washed twice by PBS, and then washed with ddH₂O every three minutes for three times before being stained with Alizarin Red S solution (Cyagen Biosciences, Guangzhou, China) for 30 min at room temperature. Afterward, the mineral deposition was observed and photographed using an inverted microscope with a digital camera. The stain was then absorbed by incubation with 10% cetylpyridinium chloride (MilliporeSigma, Billerica, MA, USA) for 1 h, and the solutions were plated on a 96-well plate with 200 μl / well. The Optical density values at 560 nm of the microplate reader (ELX808; BioTek) determined the total protein concentration.

Osteoclastogenesis assay

To determine the osteoclast differentiation *in vitro*, mBMMs were seeded into 96-well plates (8×10^3 cells/well) in triplicate with osteoclastogenic medium (complete α -MEM with 30 ng/ml M-CSF and 100 ng/ml RANKL) and various concentrations of IL-34 (0, 0.0001, 0.001, 0.01 ng/ml). Cells without treatment were regarded as controls. Cells with complete α -MEM (30 ng/ml of IL-34 and 100 ng/ml RANKL) were used to check our IL-34 worked. In the process of cultivation, the medium was changed every two days. Afterwards, cells were washed twice with PBS, fixed in 4% paraformaldehyde for 15 min, washed twice with PBS again, and stained for tartrateresistant acid phosphatase (TRAP) staining (Sigma-Aldrich, Hannover, Germany), according to the manufacturer's instructions. TRAP-positive cells with no less than two nuclei were considered as mature osteoclasts. The number and spread area of mature osteoclasts were measured by ImageJ software (National Institutes of Health, Bethesda, MD, USA).

RNA extraction and quantitative RT-PCR

Gene expression levels of osteoclast and osteoblast formation were measured by quantitative RT-PCR (qRT-PCR). hBMSCs (3×10^4 cells/cm²) and mBMMs (1×10^5 cells/well) were seeded in six-well plates and cultured in the medium. The isolation and measurement of total cellular RNA was performed using the RNAiso reagent (Takara Bio, Kusatsu, Japan) and NanoDrop 2000. The absorbance of the samples at 260 nm was calculated in accordance with the manufacturer's instructions (Thermo Fisher Scientific, MA, USA). Total RNA (#1 μ g) was reverse transcribed into complementary DNA (cDNA) in a 20 μ l reaction volume (Takara). Two μ l cDNA was used as the template with Power SYBR® Green PCR Master Mix (Takara), qRT-PCR was performed in triplicate by the ABI StepOnePlus System (Thermo Fisher Scientific). As housekeeping genes, 18S or β -actin was used, and all of the reactions were repeated three times independently. Sangon Biotech (Shanghai, China) synthesized all of the primers used in this work. Primer sequences are listed in Table 1. The qRT-PCR reaction was: 95°C for 30 s, followed by 40 cycles of 95°C for 5 s, and 60°C for 30 s. The expression levels of all of the genes were evaluated by $2^{-\Delta\Delta C_t}$ method.

TABLE 1. Sequences of primers for qRT-PCR

Gene	Primers (5'-3')	
	Forward	Reverse
h-COL1A1	CAGATCACGTCATCGCACAAAC	GAGGGCCAAGACGAAGACATC
h-RUNX2	TGGTTACTGTCATGGCGGGTA	TCTCAGATCGTTGAACCTTGCTA
h-OCN	CACTCCTCGCCCTATTGGC	CCCTCCTGCTTGGACACAAAG
h-SP7	AGCCCATTAGTGCTTGTAAGG	CCTCTGCGGGACTCAACAAC
h-ALP	ACCACCACGAGAGTGAACCA	CGTTGTCTGAGTACCAGTCCC
h-OPN	CTCCATTGACTCGAACGACTC	CAGGTCTGCGAAACTTCTTAGAT
h-18S	CCAGACAAATCGCTCCACCAAC	GACTCAACACGGGAAACCTCAC
m- β -ACTIN	TCTGCTGGAAGGTGGACAGT	CCTCTATGCCAACACAGTGC
m-NFATc1	CGTTGCTTCCAGAAAATAACA	TGTGGGATGTGAACTCGGAA
m-CATHEPSIN K	CTTCCAATACGTGCAGCAGA	TCTTCAGGGCTTTCTCGTTC
m-C-FOS	CCAGTCAAGAGCATCAGCAA	AAGTAGTGCAGCCCGGAGTA
m-CTR	TGCTGGCTGAGTGCAGAAACC	GGCCTTCACAGCCTTCAGGTAC
m-MMP-9	CAAAGACCTGAAAACCTCCAA	GGTACAAGTATGCCTCTGCCA

h-, human; m-, mice.

Western blotting analyses

To investigate the effects of IL-34 on multiple signaling pathways, hBMSCs (3×10^4 cells /cm²) and mBMMs (5×10^5 cells/well) were seeded in six-well plates and cultured in the medium. Total lysates of cells were extracted by lysis in for 30 min on ice in a ripa buffer containing with phosphatase and protease inhibitor cocktails (Beyotime). The centrifugation to clear the lysates and collect the supernatants was set at 14,000 rpm for 10 min at 4°C. After electrophoresis, the SDS polyacrylamide gel was transferred to a polyvinylidene fluoride (PVDF) membrane (MilliporeSigma), which was then probed with the primary antibodies. Then, membranes were blocked with 10% non-fat milk and 0.1% Tween in tris-buffered saline for 1 h at room temperature. Afterward, the membranes were incubated at 4°C overnight with primary antibodies. After washing with 0.1% Tween in tris-buffered saline for three times and incubation with horseradish peroxidase-conjugated secondary antibodies (anti-mouse or anti-rabbit; Beyotime) for 1 h at room temperature, proteins were visualized using an enhanced chemiluminescent detection reagent (MilliporeSigma) and an XRS chemiluminescence detection system (Bio-Rad Laboratories, Hercules, CA, USA).

Immunofluorescence assay

A 12-well plate was used to place hBMSCs in induction medium, and a fluorescence microscope (EU5888; Leica Camera, Wetzlar, Germany) was used for the evaluation of RUNX2 and COL1A1. At room temperature, the cells were treated with 4% paraformaldehyde. After 15 min, hBMSCs were permeabilized for five min with 0.1% Triton X-100 in PBS, and blocked in 2% bovine serum albumin for 30 min. Fixed

cells were washed and incubated overnight with anti-RUNX2 (1:500; CST) and anti-COL1A1 (1:500; CST). Then the fluorescence-conjugated secondary antibody (Beyotime) was added to the cells for 60 min, and DAPI (Nanjing KeyGen Biotech, Nanjing, China) was used to stain the nuclei for five min. The images were captured by a fluorescence microscope (Leica Camera) and the fields were selected randomly.

Lentiviral packaging and cell infection

A lentiviral package was applied by Cyagen Biosciences (Guangzhou, China), including lentiviral particles to overexpress IL-34 (IL-34 overexpressed (OE) group) and lentiviral GFP particles (the negative control (NC) group). hBMSCs (3×10^4 cells /cm²) were seeded in six-well plates and cultured in the medium. When hBMSCs reached at 30%–50% confluence, cells were cultured in lentiviral particles together with 5 µg/ml polybrene in the growth medium, in accordance with the manufacturer's instructions. The GFP fluorescence was regarded as the efficiency of transduction and the culture medium was replaced 12 h later. When at a confluence of 80%–90%, the cells were passaged and used the experiments here described. The qRT-PCR and Western blotting analyses were performed to determine the difference in osteo-specific genes and proteins.

ELISA

An ELISA (Mskbio, Wuhan, China) was used to evaluate the concentrations of IL-34 in the culture medium of both OE and NC. After the cells were infected with the lentiviral package and then cultured for 24 h, the medium was collected to measure the concentrations of IL-34, according to the manufacturer's instructions.

***In vivo* evaluation in animals**

This study was approved by the Institutional Animal Care and Use Committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (approval number: 2018-078). In accordance with the Animal Care and Use Committee guidelines of Zhejiang province together with the laboratory animals' care and use guidelines, we performed the animal experiments. Thirty-six male Sprague Dawley rats (eight-week-old, 200 g) from the Academy of Medical Sciences of Zhejiang Province were used as tibial bone defect or ovariectomized (OVX) models [33]. Eighteen rats were separated equally and haphazardly into three groups (n = 6 per group): (1) Blank group: defects without treatment; (2) PBS group: defects treated with PBS (negative control group treated with PBS); and (3) IL-34 group: defects treated with local injection of IL-34 (20 µl IL-34 at 0.01 ng/ml). Briefly, rats were anesthetized by intraperitoneal injection with 0.3% pentobarbital sodium (Sigma) at 30 mg/kg body weight. After wiping the knee joint with alcohol, the closed reduction and internal fixation were performed by a 1.3-mm intramedullary fixation pin set into the tibial cavity. A 5×2 mm² tibial defect was formed in all the rats nearly 7 mm from the proximal tibial growth plate by a grinding drill and penetrated through the cortex of the bone. The

operation was performed on the same leg for each group. The incision was then sewed up with 4–0 absorbable sutures. Local injection with 20 μ l IL-34 (0.01 ng/ml) in the tibial defect sites of the rats from IL-34 group every two days after operation, and the rats from rest groups were treated with (PBS group) or without (BLANK group) 20 μ l PBS. The remaining 18 rats were randomized into three groups of six rats each: sham-surgery rats treated with PBS (BLANK group), OVX rats treated with PBS (OVX group), and OVX rats treated with IL-34 (OVX + IL-34 group). One wk after ovariectomy, IL-34 (0.1 μ g/kg) or PBS was injected intraperitoneally into each OVX rat every two days. After two wk and eight wk, the rat tibial bone defects model and the OVX rat model were euthanized using excess anesthesia, respectively. No deaths or side effects occurred during the intervention. The tibia from each rat was collected and scanned by microcomputed tomography (Micro-CT). Specimens from the rat tibial bone defects model were fixed in 4% paraformaldehyde. One day later, they were decalcified by 10% ethylene diaminetetra acetic acid (EDTA, Sigma) with 0.1 M PBS (pH 7.4) for eight wk, with a mixture change per wk. After decalcification, specimens were embedded in paraffin, and sections of the proximal tibias were obtained for H&E, SO/FG, and Masson's trichrome analysis.

Micro-CT and bone histomorphometric analyses

The tibias were analyzed by a Micro-CT (Scanco Medical, Brüttisellen, Switzerland) instrument with scanning method set at an isometric resolution of 14.8 μ m with an exposure time of 300 ms. The X-ray energy settings were 70 kV and 80 μ A. Trabecular bone volume per total volume (BV/TV), trabecular bone surface per bone volume (BS/BV), mean trabecular thickness (Tb.Th), mean trabecular number (Tb.N), mean trabecular separation (Tb. Sp), and mean connectivity density (Conn-Dens) were quantified to evaluate the microstructure of the tibias.

Statistical analysis

Results are expressed as means $\pm$ SD. SPSS software (v.22.0; IBM, Armonk, NY, USA) was used to perform the statistical analyses. All of the experiments were independently accomplished no less than three times. Statistical differences were evaluated by two-tailed Student's t-test or one-way ANOVA with Bonferroni's post hoc test. A two-way ANOVA with Bonferroni multiple comparisons post hoc test was used in the comparison of the treated groups at different time points. A $P \leq 0.05$ was regarded as being significantly different.

Results

The effects of low-dose IL-34 on hBMSCs and mBMMs viability

The effects of low-dose IL-34 on hBMSCs viability at days one, three, five and seven are shown in Figure 1A. Cells treated with IL-34 from 0.0001 to 0.01 ng/ml, the viability rate of hBMSCs increased, except for

the 0.01 ng/ml at day seven condition. The effects of IL-34 on mBMMs viability are depicted in Figure S1.

Low-dose IL-34 promoted osteoblastogenesis in hBMSCs

To evaluate the role of low-dose IL-34 on bone formation, the expression of RUNX2 and COL1A1 were measured by qRT-PCR and Western blotting analysis. Meanwhile, the expression of osteocalcin (OCN), ALP, osteopontin (OPN), and zinc finger transcription factor (SP7/Osterix) were determined by qRT-PCR. IL-34 increased the expression of RUNX2 (days three and seven) and COL1A1 (day three and seven) between 0.0001 and 0.01 ng/ml except the expression of RUNX2 (days three and seven) at 0.0001 ng/ml (Figure 1B–F). The qRT-PCR analysis revealed that RUNX2 and COL1A1 mRNA expression was increased by 0.001 and 0.01 ng/ml IL-34 on day three and seven (Figure 1G–H). OCN expression was increased by IL-34 at 0.0001 to 0.001 ng/ml on day seven (Figure 1I). OPN mRNA expression was increased by IL-34 at 0.0001 to 0.01 ng/ml on day seven, and 0.001 ng/ml on day three (Figure 1J). However, there were no significant differences between ALP and SP7 expression levels under 0.0001 to 0.01 ng/ml doses on days three and seven when compared with the control group (Figure 1K–L). IL-34 positively regulated ALP activity and calcium deposit formation at 0.001 and 0.01 ng/ml (Figure 1M–P).

Low-dose IL-34 enhanced osteogenic differentiation of hBMSCs partly via the PI3K/AKT and ERK signaling pathways

To investigate the exact mechanism by which IL-34 positively regulated osteoblastogenesis, western blotting was applied to measure whether IL-34 modulated the activation of the NF- κ B, MAPK, PI3K/AKT and Wnt/ β -catenin signaling pathways, and the results were quantified (Figure 2A–G). The phosphorylation level of AKT and ERK increased significantly after IL-34 treatment at all of the concentrations on days three and seven when compared with the control group (Figure 2B, E). However, the phosphorylation levels of the other proteins were not affected by IL-34 (Figure 2B, E). The total levels of all proteins showed no significant difference among different groups (Figure 2C, F). The phospho-protein/total-protein of AKT and ERK were significantly different between the treated groups and control group (Figure 2D, G). To further elucidate the effects of the PI3K/AKT and ERK signaling pathways on the regulation of hBMSCs osteoblastogenesis by IL-34, the IL-34-induced inhibitory effects of these two pathways on bone formation were analyzed.

As Figure 3A–B showed, there was a significant difference between control group without U0126 and treated groups with U0126 at 10, 25, and 50 μ M respectively when hBMSCs cultured in the ODM during osteogenic differentiation. We chose 25 μ M as the U0126 concentration in the following experiment. The increased expression of COL1A1, RUNX2, and P-ERK caused by the IL-34 (0.001 ng/ml) treatment was significantly inhibited when the cells were cultured with U0126 for three days (Figure 3C–F), whereas there was no difference among these groups in the expression of T-ERK (Figure 3G). The P-ERK/T-ERK was

significant decreased when cells cultured with U0126 (Figure 3H). A similar decrease was observed in the ALP activity and ARS following the addition of U0126 for three days (Figure 3I-L).

Cells treated with MK-2206 (5, 12.5, and 25 μ M) were significantly different from the control group (Figure 4A-B). Five μ M of MK-2206 was the concentration used in the follow-up work. There was a great decrease among the COL1A1, RUNX2, and P-AKT expression levels after the cells were incubated with MK-2206 for three days (Figure 4C-F). However, the expression of T-AKT did not change (Figure 4G). The P-AKT/T-AKT was significant decreased when cells cultured with MK-2206 (Figure 3H). ALP activity and ARS performed a similitude consequence after treatment with MK-2206 (Figure 4I-L).

An IF assay was performed to further assess the effects of the PI3K/AKT and ERK signaling pathways. Higher COL1A1 and RUNX2 expression levels were observed in the IL-34 treatment group relative to the control group, and the levels of both were higher than in the groups treated with inhibitors (Figure 3M-P and Figure 4M-P).

The effects of endogenously overexpressed IL-34 on osteogenesis and the expression of osteoblast-related genes and proteins *in vitro*

A IL-34 overexpression hBMSC cell line was constructed using a lentiviral vector to demonstrate the effects of endogenous IL-34 further. After infection, the cells were screened for GFP fluorescence. Three days later, the expression levels of COL1A1, RUNX2, P-ERK, T-ERK, P-AKT, T-AKT, and IL-34 were determined by western blotting analyses. Measured up against the control group, all of the proteins levels were significantly increased, except T-ERK and T-AKT (Figure 5A-F). The P-ERK/T-ERK and P-AKT/T-AKT were significant increased (Figure 5G). The expression levels of osteo-specific genes were assessed by qRT-PCR. COL1A1, RUNX2, OCN, and OPN were significantly increased in the OE group (Figure 5L-O). However, there was no difference in ALP and SP7 (Figure 5P-Q). The results of ELISA, ALP activity and ARS further confirm these above conclusions (Figure 5H-K).

Addition of exogenous low-dose IL-34 accelerated bone healing in a rat tibial osteotomy model

To complement the previous experiment, the effect of an exogenous low-dose of IL-34 on bone healing was performed. After two wks, Micro-CT analysis revealed that the bone defect was present legibly in the Blank and PBS groups (Figure 6A). In the IL-34 group, this gap was obscured, and more bridging callus formation was significantly presented in the operation area compared to the Blank and PBS groups. Quantitatively, by contrasted with the Blank and PBS group, there was an evident increase of fractures in the IL-34 group in the BV/TV, BS/BV, Tb.Th, Tb.N, and Tb. Sp (Figure 6C-G). Histological analysis revealed that there was less bridging bone formed in the operated area in the Blank and PBS groups, and a better cortex callus formation was observed in the IL-34 group by contrasted with the rest groups (Figure 6B).

Low-dose IL-34 has no effect on osteoclastogenesis

The expression of osteoclast-related genes and proteins was not affected by the exogenous low-dose IL-34 in the experimental groups by contrasted with the control group (Figure 7A-F, J-N). In addition, the results of TRAP staining and Micro-CT analysis of OVX rat models were in line with the conclusion (Figure 7G-I, O-U). Thus, the low-dose IL-34 had no effect on osteoclast formation. Our IL-34 was confirmed worked by TRAP staining with a concentration of 30 ng/ml (Figure S2A-C). A simple diagram for this experiment was shown in Figure 6H.

Discussion

IL-34, the second ligand for CSF-1R, was identified on a functional screening of a library of proteins secreted by the embryonic kidney cell line transfected with recombinant cDNAs [12]. Although, structurally, it is markedly different from any other proteins, IL-34 binds to the CSF-1 receptor strongly and is similar to CSF-1 in the ability to enhance monocyte viability and osteoclast generation [12, 13, 32, 34]. In addition, IL-34 has been regarded as a promising clinical biomarker and therapeutic target for IA [14, 20, 21]. Studies using concentrations of IL-34 above 2.5 ng/ml have reported effects on the differentiation, proliferation, and survival of osteoclasts [13, 22, 23, 35]. However, the effect of IL-34 on the bone metabolism, particularly when low doses are used, has rarely been described. Similarly, IL-34 has not been linked to the effects of osteogenic differentiation in hBMSCs. Finally, there is no description to date of a role for IL-34 in the molecular mechanisms of the osteogenesis. Here, to our knowledge, we first revealed the underlying mechanisms of low-dose IL-34 on the regulation of bone homeostasis. IL-34 promoted the bone formation of hBMSCs partly via the PI3K/AKT and ERK signaling pathways *in vitro*. Meanwhile, a rat tibial bone defect model with a local injection of IL-34 produced a better recovery *in vivo*. However, low-dose IL-34 did not contribute to the differentiation of mBMMs *in vitro*, and a rat OVX model gave results consistent with this conclusion. These observations demonstrate that low-dose IL-34 enhances the osteogenic differentiation of hBMSCs, at least by partial activation of the PI3K/AKT and ERK signaling pathways, but it has no effect on osteoclastogenesis.

Serum IL-34 levels in healthy people were found to be 152.0 (92.0–234.0) pg/ml, 56.74 ± 2.30 pg/ml or 49.1 ± 78.5 pg/ml [13, 15-17, 22, 23]. Thus, in the present study, we regarded the concentration of IL-34 in a range from 0.0001 to 0.01 ng/ml as a low dose. Chen et al. revealed that IL-34 together with RANKL can induce the formation of murine osteoclasts from not only splenocytes but also bone marrow cells in a dose-dependent manner (2.5 ng/ml, 25 ng/ml, and 100 ng/ml) and these cells have bone resorption activity [13]. According to Nakamichi et al. IL-34 appears to play a pivotal role in the generation and storage of osteoclast precursors in the spleen and osteoclastogenesis in *CSF-1^{op/op}* mice [22]. A study conducted by Cheng et al. first demonstrated that IL-34 was conducive to the survival of osteoclast progenitors and further promoted RANKL-induced osteoclast formation by the JAK2/STAT3 pathway *in vitro* [23]. Furthermore, it has been reported that TNF- α up-regulates osteoclastogenic cytokine IL-34 production through the activation of NF- κ B and JNK signaling in the synovial cells of rheumatoid arthritis (RA) patients [35]. In the present study, we revealed that a low-dose IL-34 obviously heightened the

expression of osteogenic-specific genes and proteins in hBMSCs, which filled a blank by showing that IL-34 plays an important role in osteogenesis. However, no significant differences were observed during osteoclastogenesis with the low-dose IL-34. This may be associated with the concentration of IL-34, which was too low to work for osteoclast formation both *in vivo* and *in vitro*. These results demonstrated that in low dose, IL-34 contribute to osteoblastogenesis rather than osteoclastogenesis.

Given that IL-34 has been demonstrated to play dominant roles in synovial inflammation and bone erosion, it is possibly led to RA and osteoarthritis (OA) pathology [12]. Plenty of studies have concentrated on the underlying correlation between the concentrations of IL-34 in the circulation or joint fluid and clinical parameters of RA patients. A case-control study containing with 100 RA patients and 59 healthy controls not only measured serum IL-34 levels in RA patients and healthy controls but also observed that serum IL-34 levels were significantly greater in RA patients than in healthy controls (603.5 [123.3–1,673.0] vs. 152.0 [92.0–234.0] pg/ml) [15]. These conclusions agreed with the results conducted by Wang et al., who pointed out that serum IL-34 levels in RA patients were markedly higher than in healthy controls (269.72 ± 14.71 pg/ml vs. 56.74 ± 2.30 pg/ml) [16]. The concentrations of IL-34 levels in serum were found to be correlated with several clinical variables [15, 16]. Moon et al. indicated that the serum IL-34 levels in RA patients were much higher than in OA patients and healthy controls. The mean serum IL-34 levels were 49.1 ± 78.5 pg/ml, 36.6 ± 38.0 pg/ml, and 188.0 ± 550.3 pg/ml in healthy controls, OA, and RA patients, respectively [17]. All of these previous findings supported the concept that a high-dose serum IL-34 level is a risk factor for both RA and OA. Thus, IL-34 has the classical actions, including a possibility to generate bone erosion, and may play a key role in the formation of RA and OA. However, the role of low-dose IL-34 in bone metabolism was still unclear. In our study, we focused on the relationship between low-dose IL-34 and bone metabolism, revealing that IL-34 from 0.0001 to 0.01 ng/ml contributed to osteoblastogenesis. The effects of IL-34 on hBMSCs during osteogenesis were evaluated by qRT-PCR and Western blotting analysis, revealing that IL-34 increased osteo-specific genes and proteins at lower concentrations, especially 0.001 ng/ml. ALP staining and ARS are early and late markers, respectively, of osteoblastic differentiation [3, 31, 36]. We found that IL-34 intensified ALP activity and deepened mineralization at lower concentrations, especially at 0.001 ng/ml. Those results suggested that low-dose IL-34 promoted the osteogenesis of hBMSCs *in vitro*. Meanwhile, we also observed that low-dose IL-34 has no effect on osteoclastogenesis both *in vivo* and *in vitro* (Figure 7).

The specific tyrosine residues increasingly dimerized and autophosphorylated intracellularly by the association of IL-34 with the extracellular domain of CSF-1R, leading to the accomplishment of kinds of kinases and adaptor proteins. Such players can be found in signaling pathways, including ERK and AKT [37]. These pathways enhance the pleiotropy of IL-34-mediated CSF-1R when cells differentiated, attached, migrated and proliferated. Furthermore, they stimulate cellular cytoskeletal organization and survival, subsequently modulate the specific genes expression [38]. As shown in Figure 2, our research

described an obvious increase in the expressions of P-AKT and P-ERK during the hBMSCs-driven differentiation with endogenous IL-34.

Various specific molecules could activate PI3K/AKT pathways for MSCs, such as IL-37, PDGFR β , NANOG and so on [3, 39, 40]. Several studies have emphasized the key role of the PI3K/AKT signaling pathway for all of the periods of osteogenic differentiation, maturation, and bone formation [37-38, 41]. Not only chondrocyte differentiation would be impaired, but also longitudinal bone growth would be inhibited by blocking the PI3K/AKT signaling pathway [3, 42]. With the activation of the PI3K/AKT signaling pathway, IL-34 switched the phenotype of Kupffer cells from M1 to M2 *in vitro* [43]. Chen et al. mentioned that IL-34, which is expressed and secreted by embryonic stem cells, may be responsible for ESC-promoted macrophage survival by activating the ERK1/2 and PI3K/AKT pathways [44]. In this study, we found that IL-34 enhanced bone formation by activating the PI3K/AKT signaling pathway. An inhibitor specific for the PI3K/AKT pathway significantly inhibited P-AKT. Western blotting analyses, ALP staining, ARS, and IF analyses further confirmed the regulatory role of the IL-34-PI3K/AKT axis in the osteogenic differentiation of BMSCs.

The ERK pathway, one of MAPK signaling pathways, is an important signal transducer in the regulation of the osteoblastogenesis of MSCs and bone metabolism [45]. It has been reported that major secreted ligands that regulate osteoblast activity seem to serve partly via the ERK pathway [46]. In accordance with previous studies, plenty of specific molecules, such as PDGFR β , FOXA2, and Withanolide B, could activate ERK pathways for MSCs [39, 47, 48]. The expression levels of RUNX2 and Osterix are firmly associated with ERK phosphorylation [49]. Matsushita et al. found a critical role for ERK in osteoblast mineralization because mice with *Erk1* and *Erk2* deletions display dramatically reduced bone mineralization [50]. Further, IL-34 modulates rheumatoid synovial fibroblasts proliferation and migration via the ERK/AKT signaling pathway [51]. According to the experimental results, such as western blotting, ALP staining, ARS, and IF analyses, we found ERK signaling pathway is firmly correlated to osteogenesis in hBMSCs. In order to further verify our results, an inhibitor (U0126) specific for ERK signaling pathway was applied. Treatment with U0126 blocked ERK1/2 phosphorylation and significantly decreased RUNX2, COL1A1, P-ERK, ALP activity, and mineralized nodule formation when compared with the control group. Based on the results above, we demonstrated that ERK signaling pathway is quite important in IL-34-induced osteogenesis in hBMSCs.

The relationship between cytokines and bone metabolism has been demonstrated by several studies [13, 21, 23, 35]. Nevertheless, this is the first study, to the best of our knowledge, to demonstrate the effect of low-dose IL-34 on the dynamic balance of bone metabolism, as shown in Figure 6H, and we believe it will contribute to the understanding of the relationship between bone fraction and inflammation and between

the MSCs and inflammation. Furthermore, our findings provide a new thinking and experiment data for clinical studies in the treatment of many aspects of bone healing, namely, a sustained release system of low-dose IL-34. Unfortunately, we did not investigate the impact of IL-34 on signaling molecules, such as IL-1, IL-6, IL-8 and TNF- α , that shape the inflammatory microenvironment. Moreover, the mechanisms of crosstalk between PI3K/AKT and ERK/MAPK signaling are not fully clarified and require further investigation in future studies. Finally, a rat OVX model used *in vivo* and mBMMs used for *in vitro* experiments may reveal the effect of low-dose IL-34 on osteoclastogenesis. Even though the percentage identity of human IL-34 with the rat and mouse IL-34 are 72% and 71%, respectively [12], there are still biological structural difference among different species. Thus, further studies are needed.

Conclusions

Collectively, our study first demonstrate that low-dose IL-34 regulates osteogenesis of hBMSCs partly via the PIK/AKT and ERK signaling pathway and enhances fracture healing, with neither promoting nor preventing osteoclastogenesis *in vitro* and osteoporosis *in vivo*.

Abbreviations

MSCs, mesenchymal stem cells; BMSCs, bone marrow-derived mesenchymal stem cells; hBMSCs, human bone marrow-derived mesenchymal stem cells; BMMs, bone marrow-derived macrophages; mBMMs, mice bone marrow-derived macrophages; CCK-8, cell counting kit-8; ALP, alkaline phosphatase; qRT-PCR, quantitative RT-PCR; ARS, alizarin red staining; OVX, ovariectomized; IL-6, interleukin-6; IL-8, interleukin-8; IL-34, interleukin-34; CSF-1R, colony-stimulating factor-1 receptor; RA, rheumatoid arthritis; OA, osteoarthritis; IA, inflammatory arthritis; RANKL, receptor activator of NF- κ B ligand; α -MEM, Minimum essential medium Eagle Alpha modification; M-CSF, macrophage colony-stimulating factor; rhIL-34, Recombinant human IL-34; COL1A1, collagen type I α 1 chain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RUNX2, runt-related transcription factor 2; ERK1/2, extracellular signal-regulated kinase 1/2; OCN, osteocalcin; OPN, osteopontin; AKT, protein kinase B; NFATc1, nuclear factor of activated T cells cytoplasmic 1; PGC1 β , peroxisome proliferative activates receptor gamma coactivator 1 β ; ODM, osteogenic differentiation medium; PBS, phosphate buffer saline; ddH₂O, double distilled water; TRAP, tartrateresistant acid phosphatase; OE, overpress; NC, negative control; ELISA, enzyme-linked immunosorbent assay; BV/TV, Trabecular bone volume per total volume; BS/BV, trabecular bone surface per bone volume; Tb.Th, mean trabecular thickness; Tb.N, mean trabecular number; (Tb. Sp), mean trabecular separation; Conn-Dens, mean connectivity density; SP7/Osterix, zinc finger transcription factor.

Declarations

ACKNOWLEDGEMENTS

We thank all clients from the Clinical Research Center of the Second Affiliated Hospital, Zhejiang University, including Xing Zhang, Jiayu Yang, Am Liu, and Chunc Li et al. We also appreciate the general

help of Lingl

Zhang and Sm Feng from Orthopedic Research Center of the Second Affiliated Hospital, Zhejiang University.

AUTHORS' CONTRIBUTIONS

Deting Xue and Zhijun Pan designed the research; Jianxiang Xu, Jinwu Bai, Huiming Zhong, Deting Xue and Zhijun Pan performed the experiments; Zhihui Kuang, Chengwei Zhou, Licheng Ni and Jiaqi Wu analyzed the data; Li Ying, Erman Chen, Wei Zhang and Bin Hu made the figures and tables; and Jianxiang Xu, Deting Xue and Zhijun Pan wrote the paper. Weixu Li and Lifeng Fu revised this paper and remade the figures.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All animal experiments were in accordance with the Animal Care and Use Committee guidelines of Zhejiang University. All experimental procedures were in accordance with the Institutional Animal Care Use Committee at Zhejiang University.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

FUNDING

The National Natural Science Foundation of China (Grant No. 81672147 and 81874007) funds were received in support of this work. The authors declare no relevant financial activities outside the submitted work.

COMPETING INTERESTS

The authors declare that they have no competing interests

References

1. Ding ZC, Lin YK, Gan YK, Tang TT. Molecular pathogenesis of fracture nonunion. J Orthop Translat. 2018; 14: 45-56.
2. Marongiu G, Dolci A, Verona M, Capone A. The biology and treatment of acute long-bones diaphyseal fractures: Overview of the current options for bone healing enhancement. Bone Rep. 2020; 12: 100249.
3. Ye C, Zhang W, Hang K, Chen M, Hou W, Chen J, et al. Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway. Cell death & disease. 2019; 10: 753.

4. Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: The diamond concept. *Injury*. 2007; 38: S3-S6.
5. Giannoudis PV, Einhorn TA, Schmidmaier G, Marsh D. The diamond concept – open questions. *Injury*. 2008; 39: S5-S8.
6. Pountos I, Walters G, Panteli M, Einhorn TA, Giannoudis PV. Inflammatory Profile and Osteogenic Potential of Fracture Haematoma in Humans. *J Clin Med*. 2019; 9.
7. Horst K, Greven J, Luken H, Zhi Q, Pfeifer R, Simon TP, et al. Trauma Severity and Its Impact on Local Inflammation in Extremity Injury-Insights From a Combined Trauma Model in Pigs. *Frontiers in immunology*. 2019; 10: 3028.
8. Xie Z, Tang S, Ye G, Wang P, Li J, Liu W, et al. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells. *Stem cell research & therapy*. 2018; 9: 13.
9. Niu X, Chen Y, Qi L, Liang G, Wang Y, Zhang L, et al. Hypoxia regulates angiogenic-osteogenic coupling process via up-regulating IL-6 and IL-8 in human osteoblastic cells through hypoxia-inducible factor-1alpha pathway. *Cytokine*. 2019; 113: 117-27.
10. Liu X, Chen Z, Lan T, Liang P, Tao Q. Upregulation of interleukin-8 and activin A induces osteoclastogenesis in ameloblastoma. *International journal of molecular medicine*. 2019; 43: 2329-40.
11. Wang H, Cao J, Lai X. Serum Interleukin-34 Levels Are Elevated in Patients with Systemic Lupus Erythematosus. *Molecules*. 2016; 22: 35.
12. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. *Science (New York, NY)*. 2008; 320: 807-11.
13. Chen Z, Buki K, Vääräniemi J, Gu G, Väänänen HK. The critical role of IL-34 in osteoclastogenesis. *PloS one*. 2011; 6: e18689-e.
14. Udomsinprasert W, Jittikoon J, Honsawek S. Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis. *Cytokine & growth factor reviews*. 2019; 47: 43-53.
15. Chang SH, Choi BY, Choi J, Yoo JJ, Ha YJ, Cho HJ, et al. Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis. *Rheumatology international*. 2015; 35: 71-9.
16. Wang B, Ma Z, Wang M, Sun X, Tang Y, Li M, et al. IL-34 Upregulated Th17 Production through Increased IL-6 Expression by Rheumatoid Fibroblast-Like Synoviocytes. *Mediators of inflammation*. 2017; 2017: 1567120.
17. Moon SJ, Hong YS, Ju JH, Kwok SK, Park SH, Min JK. Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis. *The Journal of rheumatology*. 2013; 40: 1842-9.
18. Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. *Annals of the rheumatic diseases*. 2012; 71: 150-4.

19. Hwang S-J, Choi B, Kang S-S, Chang J-H, Kim Y-G, Chung Y-H, et al. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. *Arthritis research & therapy*. 2012; 14: R14-R.
20. Zhou RP, Wu XS, Xie YY, Dai BB, Hu W, Ge JF, et al. Functions of interleukin-34 and its emerging association with rheumatoid arthritis. *Immunology*. 2016; 149: 362-73.
21. Li J, Liu L, Rui W, Li X, Xuan D, Zheng S, et al. New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. *Dermatology (Basel, Switzerland)*. 2017; 233: 37-46.
22. Nakamichi Y, Mizoguchi T, Arai A, Kobayashi Y, Sato M, Penninger J, et al. Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109: 10006-11.
23. Cheng X, Wan QL, Li ZB. AG490 suppresses interleukin-34-mediated osteoclastogenesis in mice bone marrow macrophages. *Cell biology international*. 2017; 41: 659-68.
24. Grabowski P. Physiology of Bone. *Endocrine development*. 2015; 28: 33-55.
25. Harada S, Rodan G. Control of osteoblast function and regulation of bone mass. *Nature*. 2003; 423: 349-55.
26. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, et al. Central control of bone remodeling by neuromedin U. *Nat Med*. 2007; 13: 1234-40.
27. Bianco P, Riminucci M, Gronthos S, Robey P. Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem cells (Dayton, Ohio)*. 2001; 19: 180-92.
28. Lin H, Sohn J, Shen H, Langhans MT, Tuan RS. Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing. *Biomaterials*. 2019; 203: 96-110.
29. Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. *Nat Med*. 2013; 19: 35-42.
30. Crane JL, Cao X. Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. *The Journal of clinical investigation*. 2014; 124: 466-72.
31. Chen E, Liu G, Zhou X, Zhang W, Wang C, Hu D, et al. Concentration-dependent, dual roles of IL-10 in the osteogenesis of human BMSCs via P38/MAPK and NF-kappaB signaling pathways. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2018; 32: 4917-29.
32. Nakamichi Y, Udagawa N, Takahashi N. IL-34 and CSF-1: similarities and differences. *Journal of bone and mineral metabolism*. 2013; 31: 486-95.
33. Xie Z, Yu H, Sun X, Tang P, Jie Z, Chen S, et al. A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Irfd1-Mediated and IkappaBalpha-Mediated p65 Nuclear Translocation. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2018; 33: 667-78.

34. Wei S, Nandi S, Chitu V, Yeung Y-G, Yu W, Huang M, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. *Journal of leukocyte biology*. 2010; 88: 495-505.
35. Amarasekara DS, Yun H, Kim S, Lee N, Kim H, Rho J. Regulation of Osteoclast Differentiation by Cytokine Networks. *Immune network*. 2018; 18: e8.
36. Hang K, Ye C, Xu J, Chen E, Wang C, Zhang W, et al. Apelin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells partly through Wnt/beta-catenin signaling pathway. *Stem cell research & therapy*. 2019; 10: 189.
37. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. *Trends in cell biology*. 2004; 14: 628-38.
38. Baghdadi M, Umeyama Y, Hama N, Kobayashi T, Han N, Wada H, et al. Interleukin-34, a comprehensive review. *Journal of leukocyte biology*. 2018; 104: 931-51.
39. Gharibi B, Ghuman MS, Hughes FJ. Akt- and Erk-mediated regulation of proliferation and differentiation during PDGFRbeta-induced MSC self-renewal. *J Cell Mol Med*. 2012; 16: 2789-801.
40. Liu F, Shi J, Zhang Y, Lian A, Han X, Zuo K, et al. NANOG Attenuates Hair Follicle-Derived Mesenchymal Stem Cell Senescence by Upregulating PBX1 and Activating AKT Signaling. *Oxid Med Cell Longev*. 2019; 2019: 4286213.
41. Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. *Journal of cell science*. 2009; 122: 716-26.
42. Ulici V, Hoenselaar KD, Gillespie JR, Beier F. The PI3K pathway regulates endochondral bone growth through control of hypertrophic chondrocyte differentiation. *BMC developmental biology*. 2008; 8: 40.
43. Zhao Z, Pan G, Tang C, Li Z, Zheng D, Wei X, et al. IL-34 Inhibits Acute Rejection of Rat Liver Transplantation by Inducing Kupffer Cell M2 Polarization. *Transplantation*. 2018; 102: e265-e74.
44. Chen T, Wang X, Guo L, Wu M, Duan Z, Lv J, et al. Embryonic Stem Cells Promoting Macrophage Survival and Function are Crucial for Teratoma Development. *Frontiers in immunology*. 2014; 5: 275.
45. Ge C, Xiao G, Jiang D, Franceschi RT. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. *The Journal of cell biology*. 2007; 176: 709-18.
46. Greenblatt MB, Shim JH, Glimcher LH. Mitogen-activated protein kinase pathways in osteoblasts. *Annual review of cell and developmental biology*. 2013; 29: 63-79.
47. Ye C, Chen M, Chen E, Li W, Wang S, Ding Q, et al. Knockdown of FOXA2 enhances the osteogenic differentiation of bone marrow-derived mesenchymal stem cells partly via activation of the ERK signalling pathway. *Cell death & disease*. 2018; 9: 836
48. Kuang Z, Bai J, Ni L, Hang K, Xu J, Ying L, et al. Withanolide B promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERK1/2 and Wnt/beta-catenin signaling pathways. *Int Immunopharmacol*. 2020; 88: 10696049. Artigas N, Urena C, Rodriguez-Carballo E, Rosa JL, Ventura F. Mitogen-activated protein kinase (MAPK)-regulated interactions between Osterix

and Runx2 are critical for the transcriptional osteogenic program. *The Journal of biological chemistry*. 2014; 289: 27105-17.

49. Matsushita T, Chan YY, Kawanami A, Balmes G, Landreth GE, Murakami S. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. *Molecular and cellular biology*. 2009; 29: 5843-57.
50. Elkhider A, Wei J, Al-Azab M, Tang Y, Walana W, Li W, et al. IL-34 modulates rheumatoid synovial fibroblasts proliferation and migration via ERK/AKT signalling pathway. *Clinical and experimental rheumatology*. 2020; 38: 479-87.

Figures

Figure 1

The effect of low-dose IL-34 on viability and osteoblastogenesis in hBMSCs. (A) A CCK-8 was used to examine the viability after cells cultured with low-dose IL-34 for 1, 3, 5 and 7 d. (B-F) The expression of RUNX2 and COL1A1 proteins were evaluated by Western blotting analysis after osteogenic differentiation for 3 and 7 d. (G-L) The expression of RUNX2, COL1A1, OCN, ALP, SP7 and OPN mRNA was determined by qRT-PCR on 3 and 7 d after osteogenic differentiation. (M and O) ALP staining and ALP activity were

performed after osteogenic differentiation for 3 d. (N and P) ARS and ARS absorbance were performed after osteogenic differentiation for 12 d. All of the experiments were independently accomplished no less than three times. Data are means $\pm$ SD. **P < 0.05 vs. the control group on 1 d, *P < 0.05 vs. the control group on 3 d, ##P < 0.05 vs. the control group on 5 d, #P < 0.05 vs. the control group on 7 d, @P < 0.05 vs. the control group on 12 d, \$P < 0.05 vs. the 1 d group at the same concentration, &P < 0.05 vs. the 3 d group at the same concentration. Scale bars, 500 μ m.

Figure 2

Low-dose IL-34 prompts activation of PI3K/AKT and ERK signaling during osteoblastogenesis in hBMSCs. (A–G) Western blotting analysis on 3 d and 7 d was performed to determine the expression of NF-κB, MAPK, PI3K/AKT and Wnt/β-catenin signaling pathways proteins on osteoblastogenesis. All of the experiments were independently accomplished no less than three times. Data are means ± SD. *P < 0.05 vs. the control group on 3 d, #P < 0.05 vs. the control group on 7 d, &P < 0.05 vs. the 3 d group at the same concentration.

Figure 3

Inhibitor specific for ERK suppresses the osteogenic differentiation caused by low-dose IL-34. (A-B) Determination of suitable concentration of inhibitor. (C-H) Expression of COL1A1, RUNX2 and ERK signaling pathway proteins was determined by Western blotting analysis on 3 d of osteogenesis. (I and K) ALP staining and activity on 3 d of osteogenesis. (J and L) ARS and quantitation on 12 d of osteogenesis. (M and O) Expression of COL1A1 proteins was determined by Immunofluorescence on 3 d of osteogenesis. (N and P) Expression of RUNX2 proteins was determined by Immunofluorescence on 3 d of osteogenesis. All of the experiments were independently accomplished no less than three times. Data are means $\pm$ SD. *P < 0.05 vs. the control group on 3 d, @P < 0.05 vs. the control group on 12 d, #P < 0.05 vs. the IL-34 (0.001 ng/ml) group. Scale bars, ALP staining and ARS, 500 μ m. Immunofluorescence, 25 μ m.

Figure 4

Inhibitor specific for PI3K/AKT suppresses the osteogenic differentiation caused by low-dose IL-34. (A-B) Determination of suitable concentration of inhibitor. (C-H) Expression of COL1A1, RUNX2 and PI3K/AKT signaling pathway proteins was determined by western blotting analysis on 3 d of osteogenesis. (I and K) ALP staining and activity on 3 d of osteogenesis. (J and L) ARS and quantitation on 12 d of osteogenesis. (M and O) Expression of COL1A1 proteins was determined by Immunofluorescence on 3 d

of osteogenesis. (N and P) Expression of RUNX2 proteins was determined by Immunofluorescence on 3 d of osteogenesis. All of the experiments were independently accomplished no less than three times. Data are means $\pm$ SD. *P < 0.05 vs. the control group on 3 d, @P < 0.05 vs. the control group on 12 d, #P < 0.05 vs. the IL-34 (0.001 ng/ml) group. Scale bars, ALP staining and ARS, 500 μ m. Immunofluorescence, 25 μ m.

Figure 5

The effects of IL-34 overexpression hBMSC cell line on osteogenic differentiation. (A-G) Expression of RUNX2, COL1A1, IL-34, P-AKT, T-AKT, P-ERK and T-ERK was determined by Western blotting on 3 d of osteogenesis. (H) The results of ELISA. (I-K) ALP staining and activity on 3 d and ARS and quantitation on 12 d of osteogenesis, respectively. (L-Q) The mRNA expression levels of COL1A1, RUNX2, OCN, OPN, ALP and SP7 were evaluated by qRT-PCR. All of the experiments were independently accomplished no less than three times. Data are means $\pm$ SD. *P < 0.05 vs. the control group on 3 d, @P < 0.05 vs. the control group on 12 d. Scale bars, 500 μ m.

Figure 6

Exogenous IL-34 enhanced bone recovering in a rat tibial osteotomy model. (A) Micro-CT analysis for bone healing. (B) Histological analysis for bone healing. H&E, hematoxylin and eosin staining. Masson, Masson's trichrome staining. Safranin O, Safranin O and fast green. (C-G) BV/TV, BS/BV, Tb.Th, Tb.N, and Tb. Sp values are presented. (H) Schematic representation of the experiments presented in this figure. All of the experiments were independently accomplished no less than three times. Data are means $\pm$ SD. * $P < 0.05$ vs. the BLANK group, # $P < 0.05$ vs. the PBS group. Scale bars, 1 mm.

Figure 7

Low-dose IL-34 has no effect on osteoclastogenesis. (A-F) The expression of NFATc1, PGC1 β , C-SRC, C-FOS and Cathepsin K was determined by western blotting on 5 d of osteoclastogenesis has no difference among various concentrations of low-dose IL-34. (G-I) mBMMs were cultured with various concentrations of low-dose IL-34 in the presence of M-CSF (30 ng/ml) and RANKL (100 ng/ml). (J-N) The mRNA expression levels of Cathepsin K, NFATc1, MMP-9, CTR, C-FOS evaluated by qRT-PCR has no difference among various concentrations of low-dose IL-34. (O) Micro-CT reconstruction images from the 3 groups at 8 wk after surgery. (P-U) BV/TV, BS/BV, Tb.Th, Tb.N, Tb. Sp, and Conn-Dens values are presented. All of the experiments were independently accomplished no less than three times. Data are means $\pm$ SD. *P < 0.05 vs. the control group. Scale bars, 1 mm.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementalfigure.docx](#)